Bristol Myers Squibb Says FDA Approved Perioperative Treatment Of Neoadjuvant Opdivo (Nivolumab) And Chemotherapy Followed By Surgery And Adjuvant Single-Agent Opdivo For Resectable Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that the FDA has approved the use of Opdivo (Nivolumab) in combination with chemotherapy for the perioperative treatment of resectable non-small cell lung cancer. This includes neoadjuvant treatment followed by surgery and adjuvant single-agent Opdivo.
October 03, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Opdivo for perioperative treatment in non-small cell lung cancer is a significant milestone for Bristol Myers Squibb, potentially boosting its market position and revenues.
The FDA approval allows Bristol Myers Squibb to expand the use of Opdivo, potentially increasing its market share in the oncology sector. This approval could lead to higher sales and revenue growth, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100